Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Calidi Biotherapeutics (CLDI) has shared an announcement.
The Company has announced a reverse stock split of its common stock at a 1-for-10 ratio, aimed at consolidating shares and possibly boosting the stock price. This strategic move, detailed in a recent press release, is significant information for investors though it’s specified not to have any legal implications for the company’s filings or liabilities under the Securities Exchange Act.
Learn more about CLDI stock on TipRanks’ Stock Analysis page.
